ALEC Share Price Performance
US$2.71
1.73 (177.89%)
6.1% undervalued intrinsic discount
US$2.88
Fair Value
Price US$2.71
AnalystConsensusTarget US$2.88
AnalystHighTarget US$6.00
AnalystLowTarget US$1.00
Fair ValueUS$2.88
Share Pricen/a
Alector, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 9 Fair Values set on narratives written by author
ALEC Community Narratives
AN
Fair Value US$2.88 6.1% undervalued intrinsic discount
Analysts Cut Alector Price Target as Latozinemab Failure Drives Valuation Shift
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
Fair Value US$6 54.9% undervalued intrinsic discount
Global Aging And Genomics Will Unlock Neurodegeneration Breakthroughs
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
Fair Value US$1 170.5% overvalued intrinsic discount
Overvaluation Will Deflate Prospects In A Niche Neurology Market
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Global Aging And Genomics Will Unlock Neurodegeneration Breakthroughs
Key Takeaways Robust pipeline progress and regulatory alignment position the company for rapid market expansion, premium pricing, and outsized revenue growth in key neurodegeneration segments. Strong platform versatility and industry interest increase potential for quick commercialization, lucrative partnerships, and accelerated long-term earnings growth.Read more
14
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
US$6
54.9% undervalued intrinsic discount
Fair Value
Profit Margin
14.75%
Future PE
242.8x
Price in 2029
US$7.41
Analysts Cut Alector Price Target as Latozinemab Failure Drives Valuation Shift
Key Takeaways Success in upcoming clinical trials could position Alector as a commercial leader in treating neurodegenerative diseases, expanding its patient reach and supporting sustained growth. Proprietary technology enables innovation and efficiency in CNS drug development, with regulatory tailwinds and strong partnerships enhancing long-term earnings prospects and de-risking the pipeline.Read more
101
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
US$2.88
6.1% undervalued intrinsic discount
Fair Value
Profit Margin
14.76%
Future PE
218.46x
Price in 2029
US$3.55
Overvaluation Will Deflate Prospects In A Niche Neurology Market
Key Takeaways Alector's limited target market and intense pricing pressures threaten future revenue growth and profit potential, even with successful regulatory outcomes. Persistent financial losses and competition from larger biotech firms increase risks of dilution, delays, and challenges in attracting resources and partnerships.Read more
10
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$1
170.5% overvalued intrinsic discount
Fair Value
Profit Margin
14.17%
Future PE
65.76x
Price in 2028
US$1.21
Trending Discussion
Recently Updated Narratives
AN
ALEC: BBB Shuttle Refocus And Cash Runway Will Support Neurodegeneration Reset
Fair Value: US$6 54.9% undervalued intrinsic discount
3 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
ALEC: BBB Shuttle Refocus Will Shape Neurodegeneration Upside Potential
Fair Value: US$2.88 6.1% undervalued intrinsic discount
3 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Overvaluation Will Deflate Prospects In A Niche Neurology Market
Fair Value: US$1 170.5% overvalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Alector, Inc. Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
- -1.30
- -484.77%
- -679.16%
- 31.6%
About ALEC
- Founded
- 2013
- Employees
- 103
- CEO
- WebsiteView website
Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer’s disease; and AL050, a GCase enzyme replacement therapy in preclinical development for the potential treatment of Parkinson’s disease and Lewy body dementia in patients having GBA1 gene mutations. The company also develops its preclinical and research pipeline comprising AL064, a tau siRNA for Alzheimer’s disease and other tauopathies; ADP062-ABC, an alpha-synuclein siRNA for Parkinson’s disease; and ADP065-ABC, an NLRP3 siRNA for neurodegenerative conditions. It has a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of progranulin-elevating monoclonal antibodies, including Latozinemab and Nivisnebart. The company was founded in 2013 and is headquartered in South San Francisco, California.
